Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Crescita Therapeutics Inc

Healthcare US CRRTF

NoneUSD
0.00(0%)

Last update at 2026-06-22T21:01:13.756187Z

Day Range

--
LowHigh

52 Week Range

0.250.56
LowHigh

Fundamentals

  • Previous Close 0.56
  • Market Cap5.98M
  • VolumeNone
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-0.15400M
  • Revenue TTM18.83M
  • Revenue Per Share TTM0.93
  • Gross Profit TTM 13.18M
  • Diluted EPS TTM-0.02

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax 0.40M -1.00900M 0.52M 3.18M 0.65M
Minority interest - - - - 0.00000M
Net income 0.86M -1.10500M 0.04M 1.85M 2.40M
Selling general administrative 10.57M 8.72M 7.13M 8.46M 10.06M
Selling and marketing expenses - - - - -
Gross profit 13.18M 10.01M 11.27M 16.54M 11.09M
Reconciled depreciation 1.47M 1.38M 1.49M 1.73M 1.15M
Ebit 0.73M -0.52900M 2.51M 3.97M 0.53M
Ebitda 2.20M 0.85M 4.00M 5.70M 1.67M
Depreciation and amortization 1.47M 1.38M 1.49M 1.73M 1.15M
Non operating income net other - - - - -
Operating income 0.53M -0.71900M 1.55M 4.97M -0.03700M
Other operating expenses 23.00M 17.49M 14.09M 17.37M 16.66M
Interest expense 0.16M 0.24M 0.25M 0.68M 0.60M
Tax provision -0.45800M 0.10M 0.48M 1.32M -1.77300M
Interest income 0.26M 0.18M 0.29M 0.28M 0.11M
Net interest income 0.10M -0.05400M 0.04M -0.40300M -0.49300M
Extraordinary items - - - - 0.00000M
Non recurring - - - - 0.00000M
Other items - - - - 0.00000M
Income tax expense -0.45800M 0.10M 0.48M 1.32M -1.77300M
Total revenue 23.52M 16.77M 15.64M 22.34M 16.63M
Total operating expenses 12.65M 10.73M 9.72M 11.57M 11.13M
Cost of revenue 10.34M 6.75M 4.37M 5.80M 5.54M
Total other income expense net -0.22700M -0.23600M -1.07400M -1.38500M 1.18M
Discontinued operations - - - - -0.02600M
Net income from continuing ops 0.86M -1.10500M 0.04M 1.85M 2.42M
Net income applicable to common shares 0.86M -1.10500M 0.04M 1.85M 2.40M
Preferred stock and other adjustments - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Total assets 28.48M 28.92M 26.83M 26.84M 27.57M
Intangible assets 2.87M 3.74M 4.61M 7.57M 8.72M
Earning assets - - - - -
Other current assets 0.39M 0.62M 0.30M 0.29M 0.27M
Total liab 7.39M 8.40M 5.70M 5.73M 8.56M
Total stockholder equity 21.10M 20.53M 21.13M 21.11M 19.01M
Deferred long term liab - - - - 0.00000M
Other current liab 5.65M 5.38M 4.32M 0.05M 0.30M
Common stock 56.30M 58.08M 58.18M 58.42M 59.22M
Capital stock 56.30M 58.08M 58.18M 58.42M 59.22M
Retained earnings -40.61300M -41.47500M -40.37000M -40.40700M -42.14300M
Other liab 0.12M 0.15M 0.15M 0.20M 0.06M
Good will - - - - 0.00000M
Other assets 2.45M 2.18M 1.98M 2.16M 1.45M
Cash 8.24M 11.33M 14.28M 9.27M 8.59M
Cash and equivalents - - - - -
Total current liabilities 6.06M 6.72M 4.62M 4.34M 5.64M
Current deferred revenue - - - - -
Net debt -6.62500M -8.46300M -13.05100M -7.72000M -4.18000M
Short term debt 0.41M 1.34M 0.30M 0.36M 1.56M
Short long term debt - 0.98M - - 1.56M
Short long term debt total 1.61M 2.87M 1.23M 1.55M 4.41M
Other stockholder equity 4.27M 2.77M 2.27M 1.95M 1.12M
Property plant equipment 2.31M 2.58M 0.79M 1.18M 0.71M
Total current assets 20.52M 20.09M 19.40M 15.92M 16.69M
Long term investments 0.34M 0.34M - - 0.00000M
Net tangible assets 18.23M 16.79M 16.52M 13.54M 10.29M
Short term investments - - - 0.06M 0.05M
Net receivables 6.24M 3.75M 1.36M 2.58M 5.13M
Long term debt - - 0.93M 0.90M 2.85M
Inventory 5.65M 4.39M 3.46M 3.78M 2.70M
Accounts payable 5.59M 5.33M 4.27M 3.94M 3.79M
Total permanent equity - - - - 0.00000M
Noncontrolling interest in consolidated entity - - - - 0.00000M
Temporary equity redeemable noncontrolling interests - - - - 0.00000M
Accumulated other comprehensive income 1.13M 1.15M 1.05M 1.15M 0.81M
Additional paid in capital - - - - 0.00000M
Common stock total equity - - - - 0.00000M
Preferred stock total equity - - - - 0.00000M
Retained earnings total equity - - - - 0.00000M
Treasury stock - - - - 0.00000M
Accumulated amortization - - - - -
Non currrent assets other 3.99M 2.18M 2.03M 1.58M -
Deferred long term asset charges - - - - -
Non current assets total 7.97M 8.83M 7.43M 10.91M 10.87M
Capital lease obligations 1.61M 1.89M 0.30M 0.65M -
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -0.29000M -0.84600M -0.05900M -0.21500M -0.14400M
Change to liabilities 0.23M 0.99M 0.33M 0.16M 0.51M
Total cashflows from investing activities -0.29000M -0.84600M -0.05900M -0.21500M -0.14400M
Net borrowings -1.37300M -0.34900M -0.35800M -3.88700M -3.88700M
Total cash from financing activities -1.84600M -0.50000M -0.47600M -4.39400M 3.19M
Change to operating activities 0.27M -0.26700M -0.14000M 0.09M 0.10M
Net income 0.86M -1.10500M 0.04M 1.85M 2.40M
Change in cash -3.09300M -2.95000M 5.01M 0.68M 1.59M
Begin period cash flow 11.33M 14.28M 9.27M 8.59M 7.00M
End period cash flow 8.24M 11.33M 14.28M 9.27M 8.59M
Total cash from operating activities -1.02000M -1.59700M 5.61M 5.31M -1.47800M
Issuance of capital stock - - - 0.00000M 3.52M
Depreciation 1.47M 1.38M 1.49M 1.73M 1.15M
Other cashflows from investing activities - -0.50000M -0.50000M -0.50000M -0.50000M
Dividends paid - - - - 0.00000M
Change to inventory -1.78000M -1.37500M -0.04100M -1.33800M 0.32M
Change to account receivables -2.57200M -1.04200M 1.25M 2.81M -3.88300M
Sale purchase of stock -0.42900M -0.10100M -0.06800M -0.25700M 0.00000M
Other cashflows from financing activities -0.04400M -0.05000M -0.05000M -0.25000M -0.33400M
Change to netincome 0.36M -0.40500M 2.50M -0.00400M -2.06600M
Capital expenditures 0.23M 0.35M 0.06M 0.21M 0.14M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -3.71500M -1.46600M 1.58M 1.73M -2.95400M
Stock based compensation 0.22M 0.27M 0.15M 0.29M 0.34M
Other non cash items 0.60M -0.77300M 1.86M -1.61600M -0.63500M
Free cash flow -1.24900M -1.94300M 5.55M 5.09M -1.62200M

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
CRRTF
Crescita Therapeutics Inc		 - -% - - - 0.32 0.39 0.15 -0.7255
ZTS
Zoetis Inc		 -2.82 3.58% 75.89 40.18 30.96 10.67 17.60 11.27 26.18
MKKGY
Merck KGaA ADR		 -0.19 0.62% 30.56 21.25 14.93 3.10 2.14 3.60 12.98
MKGAF
MERCK Kommanditgesellschaft auf Aktien		 - -% 157.12 21.73 14.95 3.16 2.15 3.56 12.82
GALDY
GALDERMA GROUP AG		 - -% 42.94 74.21 41.67 8.64 5.55 9.15 42.22

Reports Covered

Stock Research & News

View All

Profile

Crescita Therapeutics Inc., a dermatology company, provides non-prescription skincare products and prescription drug products in Canada, the United States, and internationally. The company operates through three segments: Commercial Skincare, Licensing and Royalties, and Manufacturing and Services. It owns proprietary platform technologies, including Multiplexed Molecular Penetration Enhancers (MMPE) and DuraPeel for the development of topicals containing cannabis and hemp. The company's prescription products include Pliaglis, a topical local anesthetic cream that provides dermal analgesia on intact skin prior to superficial dermatological procedures; CTX-101, a Phase III topical formulation utilizing a corticosteroid in combination with MMPE technology to treat plaque psoriasis; CTX-102, a Phase I topical formulation utilizing MMPE technology to treat an undisclosed dermatological skin condition; and dermatology products in pre-clinical formulation utilizing MMPE technology for prescription treatments of skin diseases. Its non-prescription portfolio offers dermocosmetic products, such as facial creams, cleansers, exfoliants, masks, serums, and suncare to treat mild acne, aging, dehydration, pigmentation, sensitivity, and rosacea under the Laboratoire Dr Renaud brand; and provides medical aesthetics under Pro-Derm and Alyria brands, for non-invasive and minimally invasive procedures or skincare treatments. In addition, it distributes NCTF Boost 135 HA, a skin revitalization solution; Obagi Medical products; and ART FILLER, hyaluronic acid-based dermal fillers. The company has a commercialization license agreement with Cantabria Labs Inc.; and a development and commercialization license agreement with Taro Pharmaceuticals Inc. Crescita Therapeutics Inc. was incorporated in 2016 and is headquartered in Laval, Canada.

Crescita Therapeutics Inc

2805 Place Louis-R Renaud, Laval, QC, Canada, H7V 0A3

Key Executives

Name Title Year Born
Mr. Serge Verreault B.A., M.B.A. Pres & CEO NA
Mr. Jose DaRocha C.A., CPA Chief Financial Officer NA
Mr. Francois Lafortune Exec. VP & GM NA
Dominic King-Smith VP of Bus. Devel. NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions